The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

An object of the present invention is to provide a novel rotaxane and a polyurethane using the same. The present invention provides a rotaxane having a crown ether and a chain molecule piercing through the cyclic structure of the crown ether, wherein a hydroxyl group exists at one terminal of the chain molecule, and a hydroxyl group bonds to the cyclic structure of the crown ether. The present invention further provides a polyurethane using the rotaxane as a polyol component.

An object of the present invention is to provide a novel rotaxane and a polyurethane using the same. The present invention provides a rotaxane having a crown ether and a chain molecule piercing through the cyclic structure of the crown ether, wherein a hydroxyl group exists at one terminal of the chain molecule, and a hydroxyl group bonds to the cyclic structure of the crown ether. The present invention further provides a polyurethane using the rotaxane as a polyol component.

Disclosed are a tricyclic compound as represented by general formula (I), a pharmaceutical composition containing same, and a preparation method therefor and the medical use thereof. The compound can be used for preventing and treating a variety of diseases caused by toxic aldehydes.

##STR00001##

Disclosed are a tricyclic compound as represented by general formula (I), a pharmaceutical composition containing same, and a preparation method therefor and the medical use thereof. The compound can be used for preventing and treating a variety of diseases caused by toxic aldehydes.

##STR00001##

The present disclosure provides Molecular Recognition Technology (MRT) for selectively sequestering lithium from natural and synthetic brines, leachates, or other chemical mixtures. Also disclosed herein are MRT extractants, ligands, beads and methods of making and using thereof.

The present disclosure provides Molecular Recognition Technology (MRT) for selectively sequestering lithium from natural and synthetic brines, leachates, or other chemical mixtures. Also disclosed herein are MRT extractants, ligands, beads and methods of making and using thereof.

The present invention provides an energy device having excellent properties. Also provided is a nonaqueous electrolyte solution containing a compound represented by the following Formula (1), wherein R.sup.11, R.sup.12 and R.sup.13 each independently represent an organic group having 1 to 3 carbon atoms; and R.sup.11 and R.sup.12, R.sup.11 and R.sup.13, or R.sup.12 and R.sup.13 are optionally bound with each other to form a 5-membered ring or a 6-membered ring, with a proviso that a total number of carbon atoms of R.sup.11, R.sup.12 and R.sup.13 is 7 or less. ##STR00001##

The present invention provides an energy device having excellent properties. Also provided is a nonaqueous electrolyte solution containing a compound represented by the following Formula (1), wherein R.sup.11, R.sup.12 and R.sup.13 each independently represent an organic group having 1 to 3 carbon atoms; and R.sup.11 and R.sup.12, R.sup.11 and R.sup.13, or R.sup.12 and R.sup.13 are optionally bound with each other to form a 5-membered ring or a 6-membered ring, with a proviso that a total number of carbon atoms of R.sup.11, R.sup.12 and R.sup.13 is 7 or less. ##STR00001##